GNOM News and Press, Global X Genomics & Biotechnology ETF From 05/17/20

By Ansh Chaudhary The ETF Deathwatch decreased in size in April. Twenty exchange-traded products ("ETPs") were added to the list, and 34 funds were removed. Twenty-five of those funds were removed due to increased health and nine were due to asset managers closing their funds. That so ma...

I treat ACADIA Pharmaceuticals as an attractive long-term investment opportunity based firstly on the demographic trends in the U.S. as well as in the world and secondly on diseases progressing Y/Y for which the company is developing medications. ACADIA is well prepared financially and has t...

The Healthcare sector ranks seventh out of the 11 sectors as detailed in our Q2'20 Sector Ratings for ETFs and Mutual Funds report. Last quarter , the Healthcare sector ranked sixth. It gets our Neutral rating, which is based on an aggregation of ratings of the 358 stocks in the Healthcar...

Broadly, genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So what is genetics investing? When it comes to genetics investing, companies in this niche li...

Significant technological advancements and societal shifts occurred during the 2010's decade. Yet many of these developments became so quickly engrained in our daily lives that they often went relatively unnoticed, and their impact all but forgotten. Over this next decade, the 2020s, we expect...

Despite the coronavirus concerns that have hit commodity markets and, in turn, energy and basic materials stocks, U.S. tech stocks have posted strong returns to start the year. This continues their impressive streak from 2019. But are the current tech valuations sustainable? In a recent mark...

By Vinay Thapar and Frank Caruso US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to ...

Despite the biotech industry having pockets of extreme and irrational ebullience, the largest part of the industry is systematically underfunded. It's also the highest-value-add part of the industry from a risk-adjusted basis. In this video, we have a philosophical discussion with the CEO of o...

It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and oth...

With last recession ending over 10 years ago, investors are becoming more concerned for the inevitable "next one." While attempting to accurately time a recession can be a futile exercise, adequate preparation - through gaining knowledge of defensive or countercyclical investments and thoughtf...